07:00 , Aug 13, 2015 |  BC Innovations  |  Translation in Brief

Analytics for ALL

With the help of Alacris Theranostics GmbH's analytical platform for predicting treatment responses in cancer, an international research team identified new treatment options for a rare, fatal form of acute lymphoblastic leukemia (ALL). The group...
08:00 , Feb 20, 2006 |  BioCentury  |  Strategy

A near death experience

Four years ago, with barely E1 million in the bank, Pharming Group N.V. was forced into receivership, having bitten off more than it could chew trying to develop alpha glucosidase to treat Pompe's disease in...
07:00 , May 6, 2002 |  BC Week In Review  |  Company News

Pharming Group NV other research news

Researchers published in Nature Biotechnology that transgenic cows produced in their milk functional rhLF, an iron binding protein involved in innate immunity, in quantities ranging from 0.3-2.8 g/L. The glycosylation pattern differed between naturally produced...
08:00 , Feb 26, 2001 |  BC Week In Review  |  Clinical News

Pharming preclinical data

PHAR and colleagues published in Infection and Immunity that hLF and the cationic (postiviely charged) hLF(1-11), a fragment of hLF, were effective in treating S. aureus, Listeria monocytogenes, E. coli 064 and Klebsiella pneumoniae in...
08:00 , Feb 26, 2001 |  BC Week In Review  |  Clinical News

Human Lactoferrin hLF: Phase I

PHAR reported that in a Dutch Phase I trial in 31 male volunteers hLF was well tolerated at doses up to 60 mg/kg. Pharming Group N.V. (EASD:PHAR, AEX:PHAR), Leiden, the Netherlands   Product: Human Lactoferrin hLF...